Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Hexvix cystoscopy improves treatment of patients - new phase III results
April 22nd, 2003
PhotoCure ASA has previously, in a multicenter European Phase III study, reported that Hexvix fluorescence cystoscopy identifies approximately 30% more patients with aggressive bladder cancer (carcinoma in situ) compared to standard cystoscopy. PhotoCure has now completed the second multicenter phase III study with Hexvix fluorescence cystoscopy. This study investigated whether improved detection of bladder cancer lesions with Hexvix compared to standard white light cystoscopy would lead to a more adequate treatment of the patients. The study took place at 10 university clinics in Germany and the Netherlands and included 146 patients with known or suspected bladder...
Source: Cancer Weekly (2003-04-22)
|
